117 related articles for article (PubMed ID: 31165953)
1. Correction to: Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG).
Jaeckle KA; Anderson SK; Twohy EL; Dixon JG; Giannini C; Jenkins R; Egorin MJ; Sarkaria JN; Brown PD; Flynn PJ; Schwerkoske J; Buckner JC; Galanis E
J Neurooncol; 2019 Jul; 143(3):583. PubMed ID: 31165953
[TBL] [Abstract][Full Text] [Related]
2. Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG).
Jaeckle KA; Anderson SK; Twohy EL; Dixon JG; Giannini C; Jenkins R; Egorin MJ; Sarkaria JN; Brown PD; Flynn PJ; Schwerkoske J; Buckner JC; Galanis E
J Neurooncol; 2019 Jul; 143(3):573-581. PubMed ID: 31119479
[TBL] [Abstract][Full Text] [Related]
3. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
Cohen MH; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
[TBL] [Abstract][Full Text] [Related]
4. Imatinib mesylate in the treatment of chronic myeloid leukaemia.
Druker BJ
Expert Opin Pharmacother; 2003 Jun; 4(6):963-71. PubMed ID: 12783592
[TBL] [Abstract][Full Text] [Related]
5. Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias.
Kantarjian HM; Talpaz M
Semin Oncol; 2001 Oct; 28(5 Suppl 17):9-18. PubMed ID: 11740802
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
[TBL] [Abstract][Full Text] [Related]
7. RUNX1T1 is overexpressed in imatinib mesylate-resistant cells.
Binato R; Mencalha A; Pizzatti L; Scholl V; Zalcberg I; Abdelhay E
Mol Med Rep; 2009; 2(4):657-61. PubMed ID: 21475882
[TBL] [Abstract][Full Text] [Related]
8. STI571 (Gleevec) as a paradigm for cancer therapy.
Druker BJ
Trends Mol Med; 2002; 8(4 Suppl):S14-8. PubMed ID: 11927282
[TBL] [Abstract][Full Text] [Related]
9. STI571 protects neuronal cells from neurotoxic prion protein fragment-induced apoptosis.
Pan Y; Sun L; Wang J; Fu W; Fu Y; Wang J; Tong Y; Pan B
Neuropharmacology; 2015 Jun; 93():191-8. PubMed ID: 25681617
[TBL] [Abstract][Full Text] [Related]
10. [A case of metastatic gastrointestinal stromal tumor developing a resistance to STI571 (imatinib mesylate)].
Miyake M; Takeda Y; Hasuike Y; Kashiwazaki M; Mishima H; Ikenaga M; Mano M; Takada Y; Hirota S; Tsujinaka T
Gan To Kagaku Ryoho; 2004 Oct; 31(11):1791-4. PubMed ID: 15553717
[TBL] [Abstract][Full Text] [Related]
11. Imatinib mesylate (Gleevec, Glivec): a new therapy for chronic myeloid leukemia and other malignancies.
Hernández-Boluda JC; Cervantes F
Drugs Today (Barc); 2002 Sep; 38(9):601-13. PubMed ID: 12582448
[TBL] [Abstract][Full Text] [Related]
12. Quantification of the anti-leukemia drug STI571 (Gleevec) and its metabolite (CGP 74588) in monkey plasma using a semi-automated solid phase extraction procedure and liquid chromatography-tandem mass spectrometry.
Bakhtiar R; Khemani L; Hayes M; Bedman T; Tse F
J Pharm Biomed Anal; 2002 Jun; 28(6):1183-94. PubMed ID: 12049982
[TBL] [Abstract][Full Text] [Related]
13. Pityriasis rosea associated with imatinib (STI571, Gleevec).
Konstantopoulos K; Papadogianni A; Dimopoulou M; Kourelis C; Meletis J
Dermatology; 2002; 205(2):172-3. PubMed ID: 12218236
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.
Desjardins A; Quinn JA; Vredenburgh JJ; Sathornsumetee S; Friedman AH; Herndon JE; McLendon RE; Provenzale JM; Rich JN; Sampson JH; Gururangan S; Dowell JM; Salvado A; Friedman HS; Reardon DA
J Neurooncol; 2007 May; 83(1):53-60. PubMed ID: 17245623
[TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate (Gleevec/Glivec) a molecular-targeted therapy for chronic myeloid leukaemia and other malignancies.
Nadal E; Olavarria E
Int J Clin Pract; 2004 May; 58(5):511-6. PubMed ID: 15206509
[TBL] [Abstract][Full Text] [Related]
16. Identification of differentially expressed proteins in imatinib mesylate-resistant chronic myelogenous cells.
Park J; Kim S; Oh JK; Kim JY; Yoon SS; Lee D; Kim Y
J Biochem Mol Biol; 2005 Nov; 38(6):725-38. PubMed ID: 16336789
[TBL] [Abstract][Full Text] [Related]
17. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro.
Houghton PJ; Germain GS; Harwood FC; Schuetz JD; Stewart CF; Buchdunger E; Traxler P
Cancer Res; 2004 Apr; 64(7):2333-7. PubMed ID: 15059881
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.
Wen PY; Yung WK; Lamborn KR; Dahia PL; Wang Y; Peng B; Abrey LE; Raizer J; Cloughesy TF; Fink K; Gilbert M; Chang S; Junck L; Schiff D; Lieberman F; Fine HA; Mehta M; Robins HI; DeAngelis LM; Groves MD; Puduvalli VK; Levin V; Conrad C; Maher EA; Aldape K; Hayes M; Letvak L; Egorin MJ; Capdeville R; Kaplan R; Murgo AJ; Stiles C; Prados MD
Clin Cancer Res; 2006 Aug; 12(16):4899-907. PubMed ID: 16914578
[TBL] [Abstract][Full Text] [Related]
19. STI571: targeting BCR-ABL as therapy for CML.
Mauro MJ; Druker BJ
Oncologist; 2001; 6(3):233-8. PubMed ID: 11423669
[TBL] [Abstract][Full Text] [Related]
20. [Targeted treatment of cancers with imatinib mesylate (STI571, Gleevec): results of Asco 2002].
Ray-Coquard I; Blay JY
Bull Cancer; 2002 Jun; 89(6):567-9. PubMed ID: 12135855
[No Abstract] [Full Text] [Related]
[Next] [New Search]